Replacement reagents
This article was originally published in The Gray Sheet
Executive Summary
Updated 1Replacement Reagent & Instrument Family Policy Guidance notes that manufacturers "no longer need to submit an add-to-file prior to marketing different reagent/instrument combinations (including new family members) when both have been previously cleared." The December document, which includes replace reagent and instrument terminology and discusses CLIA categorization and special 510(k)s, supersedes a June 1996 guidance (2"The Gray Sheet" Sept. 15, 1997, I&W-4)...
You may also be interested in...
Revised secondary reagents guidance will address IVD performance criteria -- FDA's Gutman.
IVD SECONDARY REAGENT GUIDANCE REVISIONS TO BE COMPLETED in the next several weeks, FDA staffers say. The changes seek to clarify two provisions of the June 1996 guidance, Steve Gutman, director of the Division of Clinical Laboratory Devices in FDA's Center for Devices and Radiological Health, said Sept. 8 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.